APSR IDI Online KlikPDPI Halaman Admin Forum Umum Facebook Page Twitter Instagram Youtube
Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma
PDPI Sumatera Utara, 21 Feb 2023 23:05:37

Gail M Gauvreau, Jens M Hohlfeld, Mark J FitzGerald, Louis-Philippe Boulet, Donald W Cockcroft, Beth E Davis, Stephanie Korn, Oliver Kornmann, Richard Leigh, Irvin Mayers, Henrik Watz, Sarah S Grant, Monish Jain, Maciej Cabanseki, Peter E Pertel, Ieuan Jones, Jean R Lecot, Hui Cao, Paul M O'Byrne
European Respiratory Journal 2023; DOI: 10.1183/13993003.01193-2022


Rationale Thymic stromal lymphopoietin (TSLP) is a key upstream regulator driving allergic inflammatory responses.

Objective We evaluated efficacy and safety of ecleralimab, a potent inhaled neutralizing antibody fragment against human TSLP, using allergen inhalation challenge (AIC) in subjects with mild atopic asthma.

Methods This was a 12-week, randomised, double-blind, placebo-controlled, parallel-design, multicentre allergen bronchoprovocation study conducted at 10 centres across Canada and Germany. Subjects aged 18–60 years with stable mild atopic asthma were randomised (1:1) to receive 4 mg once daily inhaled ecleralimab or placebo. Primary endpoints were to evaluate the allergen-induced change in forced expiratory volume (FEV1) during the late asthmatic response (LAR) measured by area under the curve (AUC3–7h) and maximum percentage fall (LAR%) on Day 84, and safety of ecleralimab. Allergen-induced early asthmatic response (EAR), sputum eosinophils and fractional exhaled nitric oxide (FeNO) were secondary and exploratory endpoints.

Measurements and Main Results Twenty-eight subjects were randomised to ecleralimab (n=15) or placebo (n=13). On Day 84, ecleralimab significantly attenuated LAR AUC3–7h by 64% (p=0.008), LAR% by 48% (p=0.029) and allergen-induced sputum eosinophils by 64% at 7 h (p=0.011) and by 52% at 24 h (p=0.047) post-challenge. Ecleralimab also numerically reduced EAR AUC0–2h (p=0.097) and EAR% (p=0.105). FeNO levels were significantly reduced from baseline throughout the study (p<0.05) except at 24 h post-allergen (Day 43 and Day 85). Overall, ecleralimab was safe and well-tolerated.

Conclusion Ecleralimab significantly attenuated allergen-induced bronchoconstriction and airway inflammation and was safe in subjects with mild atopic asthma.

Fakta Varian Omicron
Uploaded on Dec 13, 2021
Bahaya Debu Abu Vulkanik pada Kesehatan
Uploaded on Dec 10, 2021
Juara I - PDPI Cab Surakarta
Uploaded on March 27, 2022
Juara II - PDPI Cab Yogyakarta
Uploaded on March 27, 2022
Juara III - PDPI Cab Malang
Uploaded on March 27, 2022